BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21945516)

  • 1. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.
    Burger JA; Ford RJ
    Semin Cancer Biol; 2011 Nov; 21(5):308-12. PubMed ID: 21945516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Papin A; Le Gouill S; Chiron D
    Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
    Zhang H; Chen Z; Neelapu SS; Romaguera J; McCarty N
    Oncotarget; 2016 Mar; 7(12):14350-65. PubMed ID: 26885608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
    Kurtova AV; Tamayo AT; Ford RJ; Burger JA
    Blood; 2009 May; 113(19):4604-13. PubMed ID: 19228923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
    Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
    Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
    Chen Z; Teo AE; McCarty N
    Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents in mantle cell lymphoma.
    Tucker D; Rule S
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Qualls D; Kumar A; Epstein-Peterson ZD
    Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
    Chiron D; Bellanger C; Papin A; Tessoulin B; Dousset C; Maiga S; Moreau A; Esbelin J; Trichet V; Chen-Kiang S; Moreau P; Touzeau C; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2016 Dec; 128(24):2808-2818. PubMed ID: 27697772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
    Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
    Tang T; Martin P
    Curr Hematol Malig Rep; 2014 Sep; 9(3):254-61. PubMed ID: 25023397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
    Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
    Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
    Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
    Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Guan J; Huang D; Yakimchuk K; Okret S
    Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New molecular targets in mantle cell lymphoma.
    Parekh S; Weniger MA; Wiestner A
    Semin Cancer Biol; 2011 Nov; 21(5):335-46. PubMed ID: 21945517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.
    Medina DJ; Goodell L; Glod J; Gélinas C; Rabson AB; Strair RK
    Haematologica; 2012 Aug; 97(8):1255-63. PubMed ID: 22371181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.